The FDA has approved a new drug called zolbetuximab designed to attack a novel target that’s in a type of stomach cancer.
GlobalData on MSN2d
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Zacks.com on MSN3d
Gilead, MRK Report Data From Investigational Combination Study for HIVGilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...
On September 10, experts across disciplines, from infectious disease clinicians to regulators to representatives from the pharmaceutical industry, convened at the inaugural ImmunOptimize workshop in ...
With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...
An Antidiabetic Helps the Immune System Recognize Reservoirs of HIV Sep. 10, 2024 — Metformin, a drug used to treat type 2 diabetes, could help deplete the viral reservoir and eliminate it ...
The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...
High rates of virologic suppression were observed among Black patients who received long-term ART with BIC/FTC/TAF for HIV management.
The availability of such kidney transplants outside of the research setting could substantially improve organ availability ...
Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback